ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GILD Stock Price » GILD Stock News

Gilead Sciences Share News

 Gilead Sciences (mm) Stock Price
GILD Stock Price
 Gilead Sciences (mm) Stock Chart
GILD Stock Chart
 Gilead Sciences (mm) Stock News
GILD Stock News
 Gilead Sciences (mm) Company Information
GILD Company Information
 Gilead Sciences (mm) Stock Trades
GILD Stock Trades

WSJ BLOG/Health: A.M. Vitals: GSK's Hostile Human Genome Bid; Regulators Like Preventive HIV Drug

(This story has been posted on The Wall Street Journal Online's Health Blog at By Christopher Weaver Here's what's making health news this morning: The ABCs of Beating Obesity (WSJ): A new Institute of Medicine report says schools should be a "national focal point" for the prevention of obesity, requiring, for instance, at least 60 minutes of physical activity a day. GSK Makes Hostile Human Genome Sciences Bid (WSJ): GlaxoSmithKline said it would take a $2.6 billion bid to buy Human Genome directly to shareholders after its smaller partner rejected the offer as too low. Regulator Seems to Back HIV Drug (WSJ): A memo released by Food and Drug Administration regulators Tuesday said Gilead Sciences' drug Truvada could spare people at risk for HIV "infection with a serious and life-threatening illness," a sign of support for what would be the first approval of a preventive HIV medicine. Psychiatry Manual Drafters Back Down on Diagnoses (New York Times): Amid protests from therapists, scientists and patients, the nation's top psychiatry association stripped its forthcoming index of diseases of two new disorders it concluded were not supported by evidence. Senate Inquiry Into Painkiller Makers' Ties (New York Times): Senators are probing ties between pharmaceutical companies that make pain pills and the patient groups, pain specialists and other groups that have advocated for broader use of the drugs. Retired Couples May Need $240,000 for Health Care (Associated Press): Fidelity Investments estimates that retired couples will need to reserve $240,000 for health care costs over the remainder of their lives, a number that could rise if the 2010 federal health law is repealed. -For continuously updated news from The Wall Street Journal, see at

Stock News for Gilead Sciences (GILD)
10/12/201509:51:19Premarket Biotech Digest: Understanding Multiple Sclerosis, Gilead's...
10/10/201509:59:28An Analysis Of Allergan
10/09/201517:31:30Different Ways To Think About Dividend Re-Investment, Part 1
10/08/201514:07:09Statement of Changes in Beneficial Ownership (4)
10/07/201513:24:06Statement of Changes in Beneficial Ownership (4)
10/05/201516:27:55Statement of Changes in Beneficial Ownership (4)
10/05/201514:48:10Statement of Changes in Beneficial Ownership (4)
10/05/201514:12:19Statement of Changes in Beneficial Ownership (4)
10/05/201501:51:00US-amerikanische Arzneimittelzulassungsbehörde (FDA) lässt n...
10/05/201500:49:00L'ente statunitense preposto al controllo dei farmaci e degli...
10/04/201523:28:00L’administration américaine chargée des aliments et des médicaments auto...
10/02/201518:19:00U.S. Food & Drug Administration Approves New Treatment Combination...
10/01/201516:51:14Statement of Changes in Beneficial Ownership (4)
10/01/201516:48:52Statement of Changes in Beneficial Ownership (4)
10/01/201516:41:33Statement of Changes in Beneficial Ownership (4)
10/01/201516:40:10Statement of Changes in Beneficial Ownership (4)
10/01/201516:40:10Statement of Changes in Beneficial Ownership (4)
09/28/201514:10:00SEC Charges Five With Insider Trading Over 2011 Gilead Deal
09/28/201513:43:00SEC Charges Five With Insider Trading Over 2011 Gilead Deal
09/28/201509:03:00Technical Coverage on Financial and Healthcare Stocks - CBOE...

Gilead Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations